D. Powers

发表

Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity

A. Thakur, D. Chao, E. DiGiammarino, 2020, Molecular Cancer Therapeutics.

Expression of single-chain Fv-Fc fusions in Pichia pastoris.

U. Nielsen, G. Adams, L. Weiner, 2001, Journal of immunological methods.

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.

R. Dubridge, S. Watson, P. Hevezi, 2006, Journal of experimental therapeutics & oncology.

Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons

D. Estell, D. Powers, C. Fennie, 1984, Journal of virology.

The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.

Deborah L. Higgins, S. L. Young, D. Powers, 1990, Thrombosis research.

Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody

Leonard A. Smith, Thomas J. Smith, R. Blake, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Probing Steric and Hydrophobic Effects on Enzyme-Substrate Interactions by Protein Engineering

J. V. Miller, J. Burnier, D. Estell, 1986, Science.

Molecular modeling of substrate binding in wild‐type and mutant Corynebacteria 2,5‐diketo‐D‐gluconate reductases

M. Blaber, D. Powers, S. Khurana, 2000, Proteins.

A zymogenic tissue plasminogen activator variant: The Phe305→ His mutation suppresses fibrin(ogen) stimulated plasminogen activation by one chain t-PA

S. L. Young, D. Powers, S. Anderson, 1992 .

Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites.

M. Vasser, J A Wells, D. Powers, 1985, Gene.

Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing

R. Dubridge, Verónica Juan, Minhtam Doan, 2013, mAbs.

A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo

R. Dubridge, D. Chao, V. Ramakrishnan, 2007, Journal of Translational Medicine.

Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms

S. Ybarra, R. Dubridge, D. Chao, 2010, Clinical Cancer Research.

Crystal structure of 2,5-diketo-D-gluconic acid reductase A complexed with NADPH at 2.1-A resolution.

S. Anderson, M. Blaber, D. Powers, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer.

Eric Ibsen, Richard Murray, Robert L Sutherland, 2004, Molecular cancer therapeutics.

In vivo formation and stability of engineered disulfide bonds in subtilisin.

D. Powers, J. Wells, 1986, The Journal of biological chemistry.

Designing substrate specificity by protein engineering of electrostatic interactions.

R. Bott, D. Estell, D. Powers, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Importance of conformational variability in protein engineering of subtilisin

M. Ultsch, M. Struble, D. Burdick, 1987 .